The future of comprehensive cancer care
Mayo Clinic Laboratories takes the lead in designing and optimizing oncology testing based on specific cancer types. Our comprehensive test menu includes evaluations that aid in providing both diagnostic and prognostic information and treatment selection guidance across the full spectrum of malignancies. By offering testing for both acquired and inherited cancers in one place, we serve as the singular source for all cancer testing.
“tests like these assure patients get the best cancer care, as clinicians use these results to determine the best treatment strategies based on the patients tumor profile - It's really that simple.”
Benjamin Kipp, Ph.D., chair of the Division of Laboratory Genetics and Genomics
Our difference
News and updates
The latest
Learn more about how Mayo Clinic Laboratories approach to whole transcriptome RNA sequencing provides the most comprehensive detection of gene fusions in solid tumors through use of next-generation sequencing to identify fusions in 1,445 genes.
After immigrating to the United State and becoming a U.S. citizen at the age of 18, Holocaust survivor Kurt Glover-Ettrich chose to give back to his new homeland by serving a 30-year career in the U.S. military. Today, as a Mayo Clinic volunteer, Kurt is giving back in new ways for the 22 years of regular care, treatment, and laboratory testing he’s received in response to the prostate cancer diagnosis that first brought him to Mayo Clinic.
In August of 2021, 28-year-old Mike Knudson, a Twin Cities resident known for his vibrant and active lifestyle, set out on what he anticipated to be an adventurous hiking vacation to the picturesque Glacier National Park in Montana. Little did he know that this journey in nature would be the start of an unexpected life path.
In this test-specific episode of the "Answers From the Lab" podcast, Wei Shen, Ph.D., explains how Mayo Clinic Laboratories' new breast cancer panel provides rapid results to guide critical decisions about treatment and screening.
In this “Hot Topic,” Joshua Bornhorst, Ph.D., assistant professor of laboratory medicine and pathology at Mayo Clinic, reviews biomarker component testing for hepatocellular carcinoma, explains the GALAD score, and explores GALAD score testing at Mayo Clinic Laboratories.
Sounak Gupta, M.B.B.S., Ph.D., explains how Mayo Clinic Laboratories' gynecological NGS panels provide focused assessments of gynecological cancers. The cost-effective tests fill the gap between single gene assays and large cancer panels, to inform prognosis and treatment.
Sounak Gupta, M.B.B.S., Ph.D., explains how Mayo Clinic Laboratories' urologic panels efficiently inform prognosis and individualized cancer treatment. The carefully curated panels fill the void between single gene assays and large NGS panels.
It’s been more than three years since a team of specialists and genetic testing by Mayo Clinic Laboratories helped pinpoint the cause of Alexa Lofaro’s failing health. And today, she says she continues to feel “so much better” than she did when she first came to Mayo Clinic.
This week's Research Roundup feature: A stress-induced cilium-to-PML-NB route drives senescence initiation.
As someone affected by chronic liver disease, Susan Parrott knows how it feels to live in uncertainty. But every few months, the anxiety and doubt that shadow her life fade when Mayo Clinic Laboratories test results confirm her condition is in check and she can continue living life on her own terms.
Molecular biomarkers are a critical component in the treatment of adult and pediatric brain tumors. Robert Jenkins, M.D., Ph.D., explains how Mayo Clinic Laboratories' chromosomal microarray provides more comprehensive and accurate tumor analysis compared with other test methods.
After what looked like a blemish turned out to be angiosarcoma, a rare, life-threatening cancer of the blood vessels, Alison O'Neill was put on an aggressive treatment plan and regenerative approach to healing made possible by the pathologist who first diagnosed her cancer.
Cristiane (Cris) Ida, M.D., explains how Mayo Clinic Laboratories' updated neuro-oncology gene panel provides more clinically relevant information for managing adult and pediatric brain tumors.